Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: A phase II study from Indiana University

A. Kurup, C. W. Lin, D. J. Murry, L. Dobrolecki, D. Estes, C. T. Yiannoutsos, L. Mariano, C. Sidor, R. Hickey, N. Hanna

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: Recombinant human angiostatin (rhAngiostatin) functions as a potent inhibitor of angiogenesis. This study combined rhAngiostatin with a standard chemotherapy regimen in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients had chemotherapy-naïve stage IIIB (with pleural effusion) or IV NSCLC, performance status (PS) 0 or 1, no history of bleeding, brain metastasis or requirements for anti-coagulation. Patients received carboplatin (AUC 5) intravenously and paclitaxel (175 mg/m2) intravenously day 1 + subcutaneous rhAngiostatin at either 15 mg or 60 mg twice daily. Cycles were repeated every 3 weeks, for up to six cycles. Patients without progression after completing at least four cycles were continued on maintenance rhAngiostatin until disease progression. Results: Patient characteristics (n = 24) were: 16 males, median age 66 years (range 45-78), 54% PS 1, 83.3% stage IV and 62.5% adenocarcinoma. Grade 3/4 toxicities included: fatigue 47.8%, neutropenia 39.1%, dyspnea 39.1%, vascular 26.1% and infection 17.4%. The overall response rate was 39.1%, 39.1% stable disease and 21.7% progressive disease. Median time to progression was 144 days, and 1-year survival was 45.8%. Conclusions: rhAngiostatin in combination with paclitaxel and carboplatin is feasible and results in a high disease control rate in patients with advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)97-103
Number of pages7
JournalAnnals of Oncology
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Angiostatins
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Drug Therapy
Angiogenesis Inhibitors
Pleural Effusion
Neutropenia
Dyspnea
Area Under Curve
Fatigue
Blood Vessels
Disease Progression
Adenocarcinoma
Maintenance
Hemorrhage
Neoplasm Metastasis
Survival
Brain

Keywords

  • Angiogenesis
  • Carboplatin
  • Lung cancer
  • Paclitaxel
  • RhAngiostatin

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer : A phase II study from Indiana University. / Kurup, A.; Lin, C. W.; Murry, D. J.; Dobrolecki, L.; Estes, D.; Yiannoutsos, C. T.; Mariano, L.; Sidor, C.; Hickey, R.; Hanna, N.

In: Annals of Oncology, Vol. 17, No. 1, 01.01.2006, p. 97-103.

Research output: Contribution to journalArticle

Kurup, A. ; Lin, C. W. ; Murry, D. J. ; Dobrolecki, L. ; Estes, D. ; Yiannoutsos, C. T. ; Mariano, L. ; Sidor, C. ; Hickey, R. ; Hanna, N. / Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer : A phase II study from Indiana University. In: Annals of Oncology. 2006 ; Vol. 17, No. 1. pp. 97-103.
@article{9677f6f688b74d9b813b911a7b62e555,
title = "Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: A phase II study from Indiana University",
abstract = "Background: Recombinant human angiostatin (rhAngiostatin) functions as a potent inhibitor of angiogenesis. This study combined rhAngiostatin with a standard chemotherapy regimen in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients had chemotherapy-na{\"i}ve stage IIIB (with pleural effusion) or IV NSCLC, performance status (PS) 0 or 1, no history of bleeding, brain metastasis or requirements for anti-coagulation. Patients received carboplatin (AUC 5) intravenously and paclitaxel (175 mg/m2) intravenously day 1 + subcutaneous rhAngiostatin at either 15 mg or 60 mg twice daily. Cycles were repeated every 3 weeks, for up to six cycles. Patients without progression after completing at least four cycles were continued on maintenance rhAngiostatin until disease progression. Results: Patient characteristics (n = 24) were: 16 males, median age 66 years (range 45-78), 54{\%} PS 1, 83.3{\%} stage IV and 62.5{\%} adenocarcinoma. Grade 3/4 toxicities included: fatigue 47.8{\%}, neutropenia 39.1{\%}, dyspnea 39.1{\%}, vascular 26.1{\%} and infection 17.4{\%}. The overall response rate was 39.1{\%}, 39.1{\%} stable disease and 21.7{\%} progressive disease. Median time to progression was 144 days, and 1-year survival was 45.8{\%}. Conclusions: rhAngiostatin in combination with paclitaxel and carboplatin is feasible and results in a high disease control rate in patients with advanced NSCLC.",
keywords = "Angiogenesis, Carboplatin, Lung cancer, Paclitaxel, RhAngiostatin",
author = "A. Kurup and Lin, {C. W.} and Murry, {D. J.} and L. Dobrolecki and D. Estes and Yiannoutsos, {C. T.} and L. Mariano and C. Sidor and R. Hickey and N. Hanna",
year = "2006",
month = "1",
day = "1",
doi = "10.1093/annonc/mdj055",
language = "English (US)",
volume = "17",
pages = "97--103",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

T2 - A phase II study from Indiana University

AU - Kurup, A.

AU - Lin, C. W.

AU - Murry, D. J.

AU - Dobrolecki, L.

AU - Estes, D.

AU - Yiannoutsos, C. T.

AU - Mariano, L.

AU - Sidor, C.

AU - Hickey, R.

AU - Hanna, N.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Background: Recombinant human angiostatin (rhAngiostatin) functions as a potent inhibitor of angiogenesis. This study combined rhAngiostatin with a standard chemotherapy regimen in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients had chemotherapy-naïve stage IIIB (with pleural effusion) or IV NSCLC, performance status (PS) 0 or 1, no history of bleeding, brain metastasis or requirements for anti-coagulation. Patients received carboplatin (AUC 5) intravenously and paclitaxel (175 mg/m2) intravenously day 1 + subcutaneous rhAngiostatin at either 15 mg or 60 mg twice daily. Cycles were repeated every 3 weeks, for up to six cycles. Patients without progression after completing at least four cycles were continued on maintenance rhAngiostatin until disease progression. Results: Patient characteristics (n = 24) were: 16 males, median age 66 years (range 45-78), 54% PS 1, 83.3% stage IV and 62.5% adenocarcinoma. Grade 3/4 toxicities included: fatigue 47.8%, neutropenia 39.1%, dyspnea 39.1%, vascular 26.1% and infection 17.4%. The overall response rate was 39.1%, 39.1% stable disease and 21.7% progressive disease. Median time to progression was 144 days, and 1-year survival was 45.8%. Conclusions: rhAngiostatin in combination with paclitaxel and carboplatin is feasible and results in a high disease control rate in patients with advanced NSCLC.

AB - Background: Recombinant human angiostatin (rhAngiostatin) functions as a potent inhibitor of angiogenesis. This study combined rhAngiostatin with a standard chemotherapy regimen in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients had chemotherapy-naïve stage IIIB (with pleural effusion) or IV NSCLC, performance status (PS) 0 or 1, no history of bleeding, brain metastasis or requirements for anti-coagulation. Patients received carboplatin (AUC 5) intravenously and paclitaxel (175 mg/m2) intravenously day 1 + subcutaneous rhAngiostatin at either 15 mg or 60 mg twice daily. Cycles were repeated every 3 weeks, for up to six cycles. Patients without progression after completing at least four cycles were continued on maintenance rhAngiostatin until disease progression. Results: Patient characteristics (n = 24) were: 16 males, median age 66 years (range 45-78), 54% PS 1, 83.3% stage IV and 62.5% adenocarcinoma. Grade 3/4 toxicities included: fatigue 47.8%, neutropenia 39.1%, dyspnea 39.1%, vascular 26.1% and infection 17.4%. The overall response rate was 39.1%, 39.1% stable disease and 21.7% progressive disease. Median time to progression was 144 days, and 1-year survival was 45.8%. Conclusions: rhAngiostatin in combination with paclitaxel and carboplatin is feasible and results in a high disease control rate in patients with advanced NSCLC.

KW - Angiogenesis

KW - Carboplatin

KW - Lung cancer

KW - Paclitaxel

KW - RhAngiostatin

UR - http://www.scopus.com/inward/record.url?scp=29844452745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29844452745&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdj055

DO - 10.1093/annonc/mdj055

M3 - Article

C2 - 16282244

AN - SCOPUS:29844452745

VL - 17

SP - 97

EP - 103

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -